NEW YORK, Nov. 8 (GenomeWeb News) - IBM has signed separate agreements with a number of research centers to accelerate cancer research, diagnosis and treatment, the company said today.
The agreements were signed with Memorial Sloan-Kettering Cancer Center, the Molecular Profiling Institute, and the CHU Sainte-Justine Research Center- Mother and Child University Hospital Center.
IBM and Sloan-Kettering will build a system to study long-term cancer-related illnesses, identify disease trends, and determine success rates. With a $3 million technology grant from IBM, Sloan-Kettering will also integrate its hospital data and create a searchable database for pathology reports.
IBM and Molecular Profiling will jointly develop diagnostic technology. Advances from Molecular Profiling's partnership with Translational Genomics Research Institute will be shared with IBM, the company said.
IBM and CHU, a teaching hospital affiliated with the University of Montreal, will build a system based on IBM's Clinical Genomics Solution to define the genetic markers for acute lymphoblastic leukemia.
Financial details were not disclosed.